# Aktis Oncology

**Source:** https://geo.sig.ai/brands/aktis-oncology  
**Vertical:** Healthcare & Life Sciences  
**Subcategory:** Radiopharmaceuticals  
**Tier:** Challenger  
**Website:** aktisoncology.com  
**Last Updated:** 2026-04-22

## Summary

Clinical-stage oncology company completed $318M IPO in Jan 2026 — first biotech IPO of 2026 (Nasdaq: AKTS); Eli Lilly took $100M stake; developing alpha-emitting radiopharmaceutical AKY-1189 targeting Nectin-4 for bladder and other solid tumors.

## Company Overview

Aktis Oncology is a Boston-based clinical-stage oncology company developing alpha-emitting radiopharmaceuticals against prevalent solid tumors. The company completed a $318 million IPO in January 2026 — the first significant biotech IPO of 2026 — pricing 17.65 million shares at $18 each on the Nasdaq under ticker AKTS. Eli Lilly stepped in to purchase $100 million of the offering.

The company's lead candidate, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, the same protein that Pfizer's bladder cancer drug Padcev binds to. Aktis's approach uses alpha-emitting isotopes which can hit tumor targets outside the scope of other radiopharmaceuticals. A second candidate, Ac-AKY-2519, targets B7-H3 expressing tumors with an IND filing planned for 2026.

Aktis's IPO ranks as the sector's third-largest since the start of 2024, trailing only offerings from Kyverna Therapeutics and CG Oncology, and its successful debut signals renewed public market interest in companies with differentiated platforms and clear clinical milestones in precision oncology.

## Frequently Asked Questions

### What does Aktis Oncology do?
Develops alpha-emitting radiopharmaceuticals targeting solid tumors.

### What was the IPO?
$318M IPO in January 2026. Nasdaq: AKTS. First biotech IPO of 2026.

### Who is a major investor?
Eli Lilly purchased a $100M stake during the IPO.

### What is the lead drug?
AKY-1189, a miniprotein radioconjugate targeting Nectin-4 in solid tumors.

### What is Aktis Oncology's lead drug candidate and how does it work?
Aktis Oncology's lead candidate, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4—the same protein targeted by Pfizer's bladder cancer drug Padcev. Aktis uses alpha-emitting radioisotopes (specifically actinium or other alpha emitters) rather than the beta emitters used in current approved radiopharmaceuticals. Alpha particles deliver highly localized cell-killing radiation with shorter range, potentially reducing off-target toxicity in surrounding healthy tissue.

### What is Aktis Oncology's IPO story and what does it signal?
Aktis Oncology completed a $318 million IPO in January 2026—the first significant biotech IPO of 2026—pricing 17.65 million shares at $18 each on Nasdaq (ticker: AKTS). Eli Lilly purchased $100 million of the offering, signaling strategic interest. The successful IPO in a challenging biotech market validated investor enthusiasm for the radiopharmaceutical sector following the success of Novartis's Lutathera and Pluvicto.

### What is the broader radiopharmaceutical market and why is it attractive?
Radiopharmaceuticals deliver radioactive molecules directly to cancer cells, combining the targeting precision of biologics with the tumor-killing power of radiation. The sector has attracted massive investment following the billion-dollar successes of Novartis's Lutathera (GI tumors) and Pluvicto (prostate cancer). Bristol-Myers Squibb, Eli Lilly, and AstraZeneca have all made major acquisitions and investments in radiopharmaceuticals, creating strategic interest in companies like Aktis with novel approaches.

### What cancers is Aktis Oncology targeting with its pipeline?
Aktis initially targets solid tumors expressing Nectin-4, which is overexpressed in bladder cancer, breast cancer, and several other solid tumor types. The Nectin-4 target choice leverages validated biology—Pfizer's Padcev is already an approved antibody-drug conjugate against Nectin-4—while Aktis's alpha-emitting radiopharmaceutical approach offers a different mechanism that may work in patients who have progressed on ADC therapy.

### What is Aktis Oncology?
Aktis Oncology is a radiopharmaceutical company developing targeted alpha therapy cancer treatments — using alpha-particle emitting radioisotopes attached to tumor-targeting molecules to selectively kill cancer cells while sparing healthy tissue.

### How does targeted alpha therapy work?
Aktis's radiopharmaceuticals combine a targeting molecule (that binds specifically to proteins overexpressed on cancer cells) with an alpha-emitting radioisotope — delivering high-energy radiation directly to tumor cells with limited systemic toxicity.

### Why is alpha therapy gaining attention in oncology?
Alpha particles have a very short range in tissue, delivering highly localized radiation to targeted cancer cells — making alpha therapy potentially more effective and less toxic than beta radiation or systemic chemotherapy for certain tumor types.

### What is Aktis Oncology's pipeline stage?
Aktis Oncology is developing its pipeline through preclinical and early clinical stages — building toward IND filings and Phase 1 trials to establish the safety and preliminary efficacy of its targeted alpha therapy candidates.

## Tags

healthtech, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-22.*